Abstract

Dr. Malini Gopinath*, Shruthi Raju, Kripesh Kumar B. C., Sreelekshmi Vinu, Cyril Tom Mathew and
Sam Jeeva Kumar Dr. Malini Gopinath*, Shruthi Raju, Kripesh Kumar B. C., Sreelekshmi Vinu, Cyril Tom Mathew and

ABSTRACT

Background: Parkinsonism is the second most common neurodegenerative disease. Parkinson?s disease, there is a gradual loss of brain cells that make and store dopamine. Materials and Methods: A Prospective observational study was carried out for a period of 12 months and subjects were selected from the Neurology department of Cosmopolitan hospital. In the study the patients were assessed using the UPDRS, PDQL and MGL Scale and their case sheets were reviewed. Results: We analysed 104 patients. Levodopa is the mainstay as monotherapy as well as in combination with other antiparkinsonian medications. Levodopa monotherapy comprised approximately 38.46% of prescriptions in the study period, followed by Rasagiline, Amantadine and Trihexyphenidyl. Combination therapy including levodopa with either DA or other antiparkinsonian medications was 53.84% in the study period. Among the combination therapies, Levodopa + other anti- parkinsonism medications (other than DA) were the most commonly prescribed regimen. The mean of UPDRS rating score of total population has declined from 47.05+/-18.08 to 43.61+/-18.52 as compared to the initial visit at the end of study which means patient condition has improved symptomatically 7.88% by our intervention. The improvement in the medication adherence was found to be 61.33%. The improvement in quality of life was 9.19% from our intervention. Conclusion: Levodopa is the mainstay as monotherapy as well as in combination with other antiparkinsonian medications. Patient counselling had an important impact on medication adherence and quality of life of Parkinsonian Patients. Effective patient counselling and better drug compliance improved patient?s quality of life.